🇺🇸 FDA

Intelligence · Clinical Pipeline

BEONE MEDICINES AUS Pipeline

All ClinicalTrials.gov programs at BEONE MEDICINES AUS — phase, modality, and trial IDs.

Programs
122

Quick answer

BEONE MEDICINES AUS has 122 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. PD-1/PD-L1 inhibitors

    BEONE MEDICINES AUS PTY LTD

    Borderline Resectable Carcinoma

    phase 2 small molecule active

    1 trial

  2. Rituximab

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  3. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  4. Sonrotoclax

    BEONE MEDICINES AUS PTY LTD

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  5. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  6. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  10. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  11. Tunlametinib+PD-1 mAb

    BEONE MEDICINES AUS PTY LTD

    Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. ZW25 (Zanidatamab)

    BEONE MEDICINES AUS PTY LTD

    HER2-amplified Biliary Tract Cancers

    phase 2 small molecule completed

    1 trial

  13. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  14. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 2 small molecule completed

    1 trial

  15. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  16. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed Diffuse Large B-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  17. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mature B-cell Malignancies

    phase 2 small molecule completed

    1 trial

  18. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  19. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  21. Zanubrutinib, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia

    phase 2 small molecule active

    1 trial

  22. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  23. A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Selected Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  25. A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Solid tumors

    phase 1 other active

    1 trial

  26. A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced and Metastatic Solid tumors

    phase 1 other active

    1 trial

  27. A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of BG-60366 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

    BEONE MEDICINES AUS PTY LTD

    EGFR-Mutant Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  28. A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced or metastatic solid tumors including hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) breast cancer

    phase 1 other active

    1 trial

  29. A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

    BEONE MEDICINES AUS PTY LTD

    Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications

    phase 1 other active

    1 trial

  30. A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced, metastatic or unresectable solid tumors

    phase 1 other active

    1 trial

  31. A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination with Anticancer Agents in Patients With Advanced Solid Tumors

    BEONE MEDICINES AUS PTY LTD

    Advanced, or metastatic solid tumors with methylthioadenosine phosphorylase (MTAP) homozygous deletion and/or lost MTAP protein expression

    phase 1 other active

    1 trial

  32. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  33. BG-60366

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  34. BG-68501

    BEONE MEDICINES AUS PTY LTD

    Breast Cancer

    phase 1 small molecule active

    1 trial

  35. BG-71332

    BEONE MEDICINES AUS PTY LTD

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  36. BG-75098

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  37. BG-75202

    BEONE MEDICINES AUS PTY LTD

    Breast Cancer

    phase 1 small molecule active

    1 trial

  38. BG-89894

    BEONE MEDICINES AUS PTY LTD

    Advanced or Metastatic MTAP-deleted Solid Tumors

    phase 1 small molecule terminated

    1 trial

  39. BG-A3004

    BEONE MEDICINES AUS PTY LTD

    Skin Diseases

    phase 1 mab active

    1 trial

  40. BG-C0902

    BEONE MEDICINES AUS PTY LTD

    Solid Tumors

    phase 1 small molecule active

    1 trial

  41. BG-C0979

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  42. BG-C137

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  43. BG-C477

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  44. BG-C9074

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  45. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Mature B-cell Malignancies

    phase 1 small molecule active

    1 trial

  46. BGB-15025

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  47. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic Spontaneous Urticaria

    phase 1 small molecule active

    1 trial

  48. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does BEONE MEDICINES AUS have?

122 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.